Episode

New Drug Offers Hope for Head and Neck Cancer

Podcast
US News Today | 2 Min News | The Daily News Now!
Published
May 30, 2026
Duration seconds
107
Processing state
not_requested
Canonical source
https://api.fastcast.ai/audio/bfc89755-7c50-4d46-a671-8b1afb1e26d4.mp3
Audio
https://api.fastcast.ai/audio/bfc89755-7c50-4d46-a671-8b1afb1e26d4.mp3
JSON
/v1/public/podcasts/us-news-today-2-min-news-the-daily-news-now-7023297/episodes/new-drug-offers-hope-for-head-and-neck-cancer
Markdown
/podcast/us-news-today-2-min-news-the-daily-news-now-7023297/new-drug-offers-hope-for-head-and-neck-cancer.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/us-news-today-2-min-news-the-daily-news-now-7023297/episodes/new-drug-offers-hope-for-head-and-neck-cancer/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/us-news-today-2-min-news-the-daily-news-now-7023297/new-drug-offers-hope-for-head-and-neck-cancer.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

A groundbreaking new drug, amivantamab, is rewriting the playbook for advanced head and neck cancer—offering hope where none existed before. In trial OrigAMI-4, over 100 patients who’d failed standard treatments saw tumors shrink or vanish, with 15 achieving complete remission. This triple-action drug targets cancer’s fuel, dodges its defenses, and rallies the immune system—all via a simple injection. Real-life impact? One patient, Carl Walsh, went from struggling with tongue cancer to savoring steak again. For HPV-negative cancers, notoriously tough to treat, the median survival jumped to 12.5 months. Experts call it a major leap forward—a beacon of hope for patients with few options left. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/78d834c063847da9